| Literature DB >> 19196898 |
Peter Kokkinos1, Jonathan Myers, Eric Nylen, Demosthenes B Panagiotakos, Athanasios Manolis, Andreas Pittaras, Marc R Blackman, Roshney Jacob-Issac, Charles Faselis, Joshua Abella, Steven Singh.
Abstract
OBJECTIVE: The purpose of this study was to assess the association between exercise capacity and mortality in African Americans and Caucasians with type 2 diabetes and to explore racial differences regarding this relationship. RESEARCH DESIGN AND METHODS: African American (n = 1,703; aged 60 +/- 10 years) and Caucasian (n = 1,445; aged 62 +/- 10 years) men with type 2 diabetes completed a maximal exercise test between 1986 and 2007 at the Veterans Affairs Medical Centers in Washington, DC, and Palo Alto, California. Three fitness categories were established (low-, moderate-, and high-fit) based on peak METs achieved. Subjects were followed for all-cause mortality for 7.3 +/- 4.7 years.Entities:
Mesh:
Year: 2009 PMID: 19196898 PMCID: PMC2660444 DOI: 10.2337/dc08-1876
Source DB: PubMed Journal: Diabetes Care ISSN: 0149-5992 Impact factor: 17.152
Demographic and clinical characteristics for African Americans and Caucasians with type 2 diabetes
| Total | African American | Caucasian |
| |
|---|---|---|---|---|
|
| 3,148 | 1,703 | 1,445 | — |
| Age (years) | 61 ± 10 | 60 ± 10 | 62 ± 10 | <0.001 |
| BMI (kg/m2) | 30 ± 5.6 | 30 ± 5.5 | 30 ± 5.7 | 0.27 |
| Resting heart rate (beats/min) | 76 ± 14 | 76 ± 14 | 76 ± 14 | 0.82 |
| Resting systolic blood pressure (mmHg) | 135 ± 21 | 136 ± 22 | 134 ± 21 | 0.1 |
| Resting diastolic blood pressure (mmHg) | 80 ± 12 | 81 ± 12 | 78 ± 12 | <0.001 |
| CVD (%) | 49.7 | 51.7 | 47.3 | <0.001 |
| Smoking (%) | 42 | 35.1 | 50.2 | <0.001 |
| Hypertension (%) | 73.6 | 75.6 | 71.3 | 0.007 |
| Family history of coronary heart disease | 14.8 | 12.3 | 18.8 | <0.001 |
| Dyslipidemia (%) | 26.9 | 34.6 | 17.9 | <0.001 |
| β-Blockers (%) | 18.3 | 13.1 | 24.4 | <0.001 |
| Calcium channel blockers (%) | 21.4 | 20.6 | 22.4 | 0.23 |
| ACE inhibitors (%) | 37.5 | 34.6 | 40.9 | <0.001 |
| Diuretics (%) | 15.7 | 18.6 | 12.3 | <0.001 |
| Aspirin (%) | 5.9 | 5.9 | 5.8 | 0.511 |
| Statins (%) | 14.6 | 9.4 | 20.7 | <0.001 |
| Insulin (%) | 30.7 | 33.7 | 22.8 | <0.001 |
| Oral glycemic agents (%) | 34.2 | 33.2 | 36.8 | 0.13 |
| Exercise data | ||||
| Peak heart rate (beats/min) | 135 ± 25 | 138 ± 25 | 131 ± 25 | <0.001 |
| Peak systolic blood pressure (mmHg) | 183 ± 32 | 188 ± 33 | 176 ± 31 | <0.001 |
| Peak diastolic blood pressure (mmHg) | 86 ± 16 | 89 ± 16 | 82 ± 15 | <0.001 |
| Peak METs (3.5 ml O2 · kg−1 · min−1) | 6.4 ± 2.3 | 6.3 ± 2.0 | 6.5 ± 2.6 | 0.001 |
Data are means ± SD.
*P values represent comparisons between African Americans and Caucasians.
HRs (95% CI) for all-cause mortality according to exercise capacity
| HR (95% CI) |
| |
|---|---|---|
| All ( | ||
| Peak exercise capacity (for each 1-MET increment) | 0.79 (0.76–0.82) | <0.001 |
| Adjusted for age and BMI | 0.82 (0.79–0.86) | <0.001 |
| Adjusted for age, BMI, cardiovascular risk factors, CVD, and cardiovascular medications | 0.84 (0.81–0.87) | <0.001 |
| African Americans ( | ||
| Peak exercise capacity (for each 1-MET increment) | 0.80 (0.76–0.84) | <0.001 |
| Adjusted for age and BMI | 0.85 (0.93–0.96) | <0.001 |
| Adjusted age, BMI, cardiovascular risk factors, CVD, and cardiovascular medications | 0.86 (0.82–0.90) | <0.001 |
| Caucasians ( | ||
| Peak exercise capacity (for each 1-MET increment) | 0.77 (0.73–0.82) | <0.001 |
| Adjusted for age and BMI | 0.81 (0.76–0.85) | <0.001 |
| Adjusted age, BMI, cardiovascular risk factors, CVD, and cardiovascular medications | 0.81 (0.77–0.86) | <0.001 |
*Cardiovascular risk factors include hypertension, dyslipidemia, and smoking.
†Cardiovascular medications include ACE inhibitors, β-blockers, calcium channel blockers, diuretics, insulin, aspirin, and statins.
Figure 1Cumulative survival for the entire cohort according to fitness categories.
Relative risk for all-cause mortality according to fitness categories
| Low fit | Moderate fit | High fit |
| |
|---|---|---|---|---|
| MET level achieved | ≤5 METs | 5.1–7.9 METs | ≥8 METs | |
| Entire cohort ( | ||||
| Age-adjusted | Referent | 0.62 (0.53–0.71) | 0.41 (0.32–0.52) | <0.001 |
| Multi-adjusted | Referent | 0.63 (0.55–0.73) | 0.41 (0.33–0.53) | <0.001 |
| Excluding deaths that occurred during the first year of follow-up | Referent | 0.63 (0.53–0.73) | 0.43 (0.14–0.55) | <0.001 |
| African-Americans ( | ||||
| Age-adjusted | Referent | 0.65 (0.54–0.78) | 0.54 (0.39–0.73) | <0.001 |
| Multi-adjusted | Referent | 0.66 (0.55–0.80) | 0.54 (0.39–0.73) | <0.001 |
| Excluding deaths that occurred during the first year of follow-up | Referent | 0.65 (0.53–0.79) | 0.56 (0.40–0.77) | <0.001 |
| Caucasians ( | ||||
| Age-adjusted | Referent | 0.55 (0.43–0.70) | 0.32 (0.22–0.47) | <0.001 |
| Multi-adjusted | Referent | 0.57 (0.44–0.73) | 0.33 (0.22–0.48) | <0.001 |
| Excluding deaths that occurred during the first year of follow-up | Referent | 0.57 (0.43–0.72) | 0.34 (0.23–0.51) | <0.001 |
Data are HRs (95% CI).
*P values are for both the moderate-fit and high-fit categories compared with the low-fit category (referent) and for linear trend.
†Adjusted for age, BMI, ACE inhibitors, β-blockers, calcium channel blockers, diuretics, statins, hypertension, dyslipidemia, and smoking.